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preoperative clinical predictor of pulmonary complications
after major lung resection. The results are similar to those
reported from independent centers.6,7 The results of this
study confirm the general applicability of using DLCO as
a routine measure of risk in the preoperative assessment of
lung resection candidates regardless of COPD status.
There are several potential weaknesses in this study.
The data set may not be reflective of the general popula-
tion of patients who undergo major lung resection in the
United States. Because the STS General Thoracic Surgery
Database does not have an auditing feature, whether the
data are accurate and reflect all of the patients treated at
participating sites are unknown. A large number of pa-
tients were excluded from this study because information
on DLCO was lacking. Whether this information was lack-
ing because it was never obtained or because it was not en-
tered into the database is not certain. A number of
differences existed between the groups of patients with
and without DLCO measurements, some of which were
important in the predictive models for pulmonary compli-
cations.
In summary, we found that DLCO is an independent and
strong predictor of the risk of pulmonary complications in
patients undergoing major lung resection for cancer and
that this predictive ability exists regardless of COPD status.
The lack of DLCO measurement was associated with worse
spirometric results, suggesting the possibility that physicians
who do not measure DLCO routinely before major lung resec-
tion may have indications for its measurement other than or
in addition to spirometric findings. Surgeons who elect to
forego measurement of DLCO on the basis of the absence
of classic findings of COPDwill fail to identify an important
abnormality in this factor in up to 25% of patients. We
recommend measurement of DLCO in candidates for lung
resection as an important element in the accurate assessment
of operative risk.
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Dr Kemp Kernstine (Duarte, Calif). This is a very important
study using the STS database, our database, to demonstrate that
the DLCO measurement is correlated with complications after lung
resection. This correlation was not solely in patients with COPD,
but in patients without COPD as well. What your findings tell us
is that DLCO should be measured in all patients whether they have
COPD or not, because DLCO independently is correlated with the
postoperative lung resection complication rate.
I have a couple of questions or comments. Currently, the cardiac
and congenital heart surgery databases have a quality assurance
system that is a component of each and the thoracic database
does not. Do you think that this might affect your results?
Dr Ferguson. It is true that there can be concerns raised by the
quality of the data submitted and the selection of data submitted,
and we have no way of assessing that. I think it is appropriate to
keep those concerns in mind when interpreting the data and the
results of our analysis.
Dr Kernstine. Do you recommend then that we should
encourage the STS to have a quality assurance system in our
thoracic data base?
Dr Ferguson. Absolutely.
Dr Kernstine. Then is the DLCO sufficiently standardized across
hospitals to make a generalized recommendation that all thoracic
surgeons should be performing DLCO routinely?
Dr Ferguson. It is a bit of an issue. We have found anecdotally
that the occasional patient comes to us with marginal DLCO and
whenwemeasure it, it is actually a little bit better. There are a number
of potential explanations for that. One is that there are differences inardiovascular Surgery c Volume 138, Number 6 1301
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Stechniques or reliability of results between institutions; in addition,
somepatients have had improvement, for example, in the pneumonia
that they presented with to the outside physicians that led to the in-
vestigation for possible lung cancer, resulting in an improved
DLCO on remeasurement. At least a couple of studies have performed
repeatedmeasurements on healthy patients over time, demonstrating
that, on average, the difference in DLCO measurement was about 1
percentage point. I think, in general, measurements of DLCO are
very reliable. It is not effort related on the part of the patient and it
is not subject to interpretation by someone who is reporting the
results, so on the basis of that I think it is very reliable.
Dr David Follette (Sacramento, Calif). Dr Ferguson, I com-
pletely agree with your conclusions. I do have 3 questions for you.
In a patient with COPD, it is not only DLCO but the corrected
DLCO. Is there anyway through the database that you can tellwhether
these were just the numbers or whether they were the corrected
numbers, because it can make a difference in a COPD population.
Dr Ferguson. It does make a difference and there is no way of
telling in the database which it is. If there is a difference, it is
primarily related to hemoglobin of the patient and generally gets
better if you use the corrected value than the uncorrected value,
but we have no way of distinguishing which value was reported.
Dr Follette. I found that the second and more useful test, espe-
cially coupled with the DLCO, is the carbon dioxide level on a blood
gas. A slight carbon dioxide retention and marked depression in
DLCO, in my view, is the highest risk pulmonary resection candidate
that I deal with. In the database, do they report blood gas data and
did you happen to correlate PCO2 levels with the DCLO?
Dr Ferguson. That is a good question and I agree with your gen-
eral assessment, but I do not recall whether there were blood gas
values. Certainly we did not perform any correlation between those
two. In my own institution, for example, we probably get blood gas
information on only about 30% of patients, so it is not done routinely.
Dr Follette. I know you did not present it, but I would like your
guideline as to what DLCO level puts a big red flag up in Chicago.
I have used one that is less than 40% with the red flag up for me.
The data you presented only showed a 10-point drop from normal.
What guideline do you use before you tell the patient and the refer-
ring doctors that this is a very high-risk patient?
Dr Ferguson. I try to be cautious when I am talking about
specific numbers. In Alex Brunelli’s study, they used a predicted
postoperative DLCO cutoff of 40% for distinguishing high-risk pa-
tients. That is what we use in general to distinguish between
much higher risk than so-called average risk, but it is really incre-
mental all the way. We will go so far as to operate on patients with
a postoperative predicted DLCO of maybe 30% if they seem other-
wise pretty vigorous. Everything else has to be taken into account
as well as this one number.
Dr Carolyn Reed (Charleston, SC). I think that also pertains to
my question. A couple weeks ago we had a patient with FVC/FEV1
80% of predicted, DLCO less than 40% of predicted, maximum1302 The Journal of Thoracic and Cardiovascular Soxygen consumption 20, and the patient had to have a lobectomy
to get the cancer out. Would you offer that patient a lobectomy?
Dr Ferguson.Given that DLCO, exercise testing is the additional
test I would do, and if that was as good as 20, yes, I would go with
the lobectomy.
Dr Richard Whyte (Stanford, Calif). Dr Ferguson, I have
1 question. You used the term a couple of times that the DLCO
was the strongest predictor of increased morbidity. You looked at
the P value on that. The P value was very low, but you had other
issues there that had a much higher relative risk that were still
highly statistically significant. I am wondering why you say this
is the most sensitive or this is the least likely to be a random predic-
tor. I would say that perhaps it is not the most important predictor of
a bad outcome. Could you comment on that?
Dr Ferguson. I am not a statistician. The P value is substan-
tially less than .0001, and that is the only reason we say it is the
strongest predictor. In our work with our own database in doing
backward elimination multivariable analysis, it does arise often-
times as the only predictor because most of those other things
fall out. You have to be a little careful about looking at the odds
ratios and comparing them because they are based on a variety
of different incremental changes for continuous variables. Some-
how, those have to be matched up to enable a head-to-head com-
parison. What we have elected to do sometimes is to measure
effects of a 10-year change in age, a 10-point difference in DLCO,
and so on. Whether those changes are equal to a 1-point increase
in creatinine or to a change from no hypertension to hypertension
is very hard to determine.
Dr Tara Karamlou (Portland, Ore). If I understand your find-
ings, you advocate that DLCO is able to be generalized to the entire
population. Yet in one of your earlier slides, you showed that induc-
tion chemotherapy and radiotherapy as well as, I believe, mortality,
were significantly different although you mention not importantly
different from a clinical perspective between the patients who
had DLCO measured and the subgroup who did not. Can you defend
that statement? Could it be more accurate to say that DLCO might be
more useful in patients who perhaps are going to be getting neoad-
juvant therapy or within the subgroup where you are actually mea-
suring it from your study?
Dr Ferguson. We do not have numbers of 5.5 million as in the
cardiac database, but 5500 patients is a large enough group of pa-
tients to demonstrate statistically significant differences between
the DLCO and noDLCO groups but not important clinical differences.
For example, there is difference in FEV1, but it was only 2 percent-
age points. I do think, though, it is important that we focus on DLCO
measurement in patients undergoing induction therapy, because
a number of people have demonstrated a substantial decrease in
DLCO as a result of induction chemotherapy and radiation therapy.
In our population, we measure DLCO, sometimes on multiple occa-
sions, until the DLCO gets back toward normal before we will sub-
ject them to surgery.urgery c December 2009
